Using disease-modifying therapies in sickle cell disease.

Area of Science:

• Hematology
• Pharmacology
• Genetic Medicine

Background:

• Sickle cell disease (SCD) management is limited by the inaccessibility of curative treatments like stem cell and gene therapies.
• There is a critical need for safe, effective, and affordable drug therapies for SCD patients.
• Understanding SCD pathophysiology is driving the development of new pharmacologic interventions.

Purpose of the Study:

• To review the current landscape of drug therapies for sickle cell disease.
• To highlight approved medications and those in development for SCD.
• To discuss the potential role of combination therapy in improving SCD outcomes.

Main Methods:

• Review of currently FDA-approved SCD drugs: hydroxyurea, L-glutamine, crizanlizumab, and voxelotor.
• Overview of ongoing research and development of novel SCD therapeutics.
• Analysis of the limitations of individual drug efficacy.

Main Results:

• Four drugs are currently approved by the US FDA for sickle cell disease treatment.
• Multiple additional drug candidates are in various stages of clinical trials.
• Current single-agent therapies demonstrate limited efficacy for many patients.

Conclusions:

• Drug therapy development for sickle cell disease is progressing rapidly.
• Combination therapy approaches are likely essential for achieving optimal treatment outcomes in SCD.
• Continued research is crucial to expand therapeutic options for sickle cell disease.